Xavier Darzacq
Kerry Ann Kelly
Xavier Darzacq
Founder, Director
UC Berkeley professor and Eikon Therapeutics founder. Dr. Darzacq has experience in leading fundamental research on protein interactions regulating cellular processes as well as pharma technology development, guiding Eikon’s single molecule screening strategy as its CTO.
Robert Tjian
Kerry Ann Kelly
Xavier Darzacq
Founder
UC Berkeley Professor, former President of HHMI, and co-founder of Tularik, Nurix, Eikon and Lyterian with 40+ years of molecular biology and biochemistry research in gene regulation and stem cell differentiation. Dr. Tjian is also a Science Partner at The Column Group (2007-2009 & 2016-present).
Kerry Ann Kelly
Kerry Ann Kelly
Kerry Ann Kelly
Founder, Director, Head of Operations
20+ years of leadership experience in biotech and academia. Ms. Kelly has led legal and operational teams in a variety of life science organizations, including, Eikon Therapeutics, Cleave Therapeutics, Ambit Biosciences, the Scripps Research Institute,and Sugen Inc.
Jack Ferrie
Kerry Ann Kelly
Kerry Ann Kelly
Founder
Biotech entrepreneur with a broad scientific background encompassing cell biology, chemistry, and artificial intelligence/machine learning (AI/ML). Dr. Ferrie is a founder and the CEO of Sentauri, Inc., a company that provides AI/ML solutions to accelerate research across biotech and pharma.
Amine Driouchi
Amine Driouchi
Amine Driouchi
Investigator
Previously Senior Scientist at Eikon Therapeutics. Dr. Driouchi brings deep microscopy knowledge as well as strong industry expertise in compound screening and assay development. He has led teams of scientists and engineers to execute discovery and drug-development projects.
Jackie Robaina
Amine Driouchi
Amine Driouchi
Senior Research Associate
Biotechnology professional with 5 years of industry research experience with a focus on
molecular biology and protein engineering for oncology and viral targets. Experience with leading small teams
and working in a range of environments from start-ups to global pharma companies.
Jonathan Karr
Amine Driouchi
Jonathan Karr
Associate Director of Portfolio and Strategy
Previously Swanson Fellow at The Column Group, where he sourced new therapeutic approaches and developed investment theses, leading to the formation of a seed-stage company. As a PhD student of Darzacq and Tjian, Dr. Karr focused on single-molecule microscopy and reconceptualizing mechanisms of transcription regulation.
Janeen Lim
Amine Driouchi
Jonathan Karr
VP of Operations
30+ years of operational experience in academia managing HR, Finance and Facilities for multiple research laboratories on the UC Berkeley campus and through the Howard Hughes Medical Institute.